{"entity":{"id":"idea-photoimmunotherapy-plus-pd1","kind":"idea","name":"Photoimmunotherapy as an in situ vaccine with PD-1 blockade","aka":[],"tldr":"Bursting tumour cells with light releases their contents to the immune system; adding immunotherapy might turn a local treatment into a body-wide one.","summary":"The idea is to pair photoimmunotherapy with cetuximab sarotalocan and pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma, turning a local light-activated treatment into an in situ vaccine. Rapid necrotic-type death releases tumour antigens and danger signals while leaving immune cells intact, EGFR targeting spares dendritic cells, and animal models show abscopal responses with checkpoint blockade. The hypothesis is that illuminated lesions plus pembrolizumab produce responses in non-illuminated lesions more often than pembrolizumab alone; a phase 2 has already been run in the US. The test is a randomised phase 2 in patients with an illuminable and a distant lesion, with distant-lesion response as endpoint; it addresses the cold-tumour bottleneck.","asOf":"2026-09-07","links":[{"label":"Mitsunaga et al., Cancer cell-selective in vivo near-infrared photoimmunotherapy (Nature Medicine 2011)","url":"https://doi.org/10.1038/nm.2554"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["photoimmunotherapy","checkpoint-inhibitor"],"targets":[],"drugs":["cetuximab-sarotalocan","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":["abscopal-effect","immunogenic-cell-death"],"trials":["keynote-048","keynote-412","keynote-689","nct06699212","nct07276399"],"people":[],"bottlenecks":[],"keyPapers":["paper-mitsunaga-nat-med","paper-keynote-048-lancet-2019","paper-jean-pascal-machiels-lancet-2019","paper-pembrolizumab-head-and-neck-j-clin-oncol-2017"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Photoimmunotherapy of accessible lesions plus pembrolizumab produces responses in non-illuminated lesions at a higher rate than pembrolizumab alone.","rationale":"Rapid necrotic-type death releases antigens and DAMPs while leaving immune cells intact; EGFR-targeting spares dendritic cells.","test":"Randomised phase 2 in recurrent/metastatic HNSCC with ≥1 illuminable and ≥1 distant lesion; endpoint distant-lesion response.","maturity":"early-clinical"},"route":"/ideas/idea-photoimmunotherapy-plus-pd1/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"photoimmunotherapy","kind":"technology","name":"Photoimmunotherapy & photodynamic therapy","route":"/technologies/photoimmunotherapy/"}],"drug":[{"id":"cetuximab-sarotalocan","kind":"drug","name":"Cetuximab sarotalocan","route":"/drugs/cetuximab-sarotalocan/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"abscopal-effect","kind":"term","name":"Abscopal effect","route":"/terms/abscopal-effect/"},{"id":"immunogenic-cell-death","kind":"term","name":"Immunogenic cell death","route":"/terms/immunogenic-cell-death/"}],"trial":[{"id":"nct07276399","kind":"trial","name":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","route":"/trials/nct07276399/"},{"id":"nct06699212","kind":"trial","name":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of ","route":"/trials/nct06699212/"},{"id":"keynote-048","kind":"trial","name":"KEYNOTE-048","route":"/trials/keynote-048/"},{"id":"keynote-412","kind":"trial","name":"KEYNOTE-412","route":"/trials/keynote-412/"},{"id":"keynote-689","kind":"trial","name":"KEYNOTE-689","route":"/trials/keynote-689/"}],"paper":[{"id":"paper-mitsunaga-nat-med","kind":"paper","name":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","route":"/key-papers/paper-mitsunaga-nat-med/"},{"id":"paper-keynote-048-lancet-2019","kind":"paper","name":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","route":"/key-papers/paper-keynote-048-lancet-2019/"},{"id":"paper-pembrolizumab-head-and-neck-j-clin-oncol-2017","kind":"paper","name":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study","route":"/key-papers/paper-pembrolizumab-head-and-neck-j-clin-oncol-2017/"},{"id":"paper-jean-pascal-machiels-lancet-2019","kind":"paper","name":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","route":"/key-papers/paper-jean-pascal-machiels-lancet-2019/"}],"bottleneck":[{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/"}],"roadmap":[{"id":"devices-roadmap","kind":"roadmap","name":"Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants","route":"/roadmaps/devices-roadmap/"}]}}